This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
One thousand times more soluble than L-cystine at neutral pH
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
The company reported lifetime high EBIDTA of Rs. 250 crores
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
Subscribe To Our Newsletter & Stay Updated